Yahoo! Finance: XOMA News

XOMA Presents Advantages of Its Multiple Antibody Formulation Technologies at Antibody Engineering Conference (GlobeNewswire)

Thu, 10 Dec 2009 14:00:00 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, reported results demonstrating the advantages of its monoclonal antibody technologies in the rapid development of a first-in-class multiple antibody product candidate, XOMA 3AB.

Graft-Versus-Host Disease: Failures and Future Opportunities (at Seeking Alpha)

Thu, 10 Dec 2009 09:55:52 Etc/GMT

XOMA LTD /DE/ Files SEC form 8-K/A, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; T (EDGAR Online)

Wed, 9 Dec 2009 21:18:05 Etc/GMT

XOMA Announces NASDAQ Matter Resolved With Letter of Reprimand (GlobeNewswire)

Wed, 9 Dec 2009 15:15:00 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that it received a Letter of Reprimand from the staff of The NASDAQ Stock Market LLC on December 8, 2009 for non-compliance with NASDAQ's Listing Rule 5635 in connection with XOMA's previously-announced common share financing completed on September 30, 2009.

4 More Stocks on Wall Street's Dollar Menu (at Motley Fool)

Mon, 7 Dec 2009 21:17:49 Etc/GMT

XOMA LTD /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra (EDGAR Online)

Thu, 19 Nov 2009 21:31:59 Etc/GMT

XOMA Receives NASDAQ Determination Letter (GlobeNewswire)

Thu, 19 Nov 2009 21:09:10 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, announced that it received a letter from the staff of The NASDAQ Stock Market LLC on November 13, 2009 indicating that the NASDAQ staff has concluded that XOMA's previously-announced common share financing completed on September 30, 2009 did not comply with NASDAQ's Listing Rule 5635.

Coverage initiated on XOMA Limited by Canaccord Adams (Briefing.com)

Wed, 18 Nov 2009 12:22:35 Etc/GMT

XOMA Appoints Jim Neal Vice President of Business Development (GlobeNewswire)

Tue, 17 Nov 2009 13:00:00 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced that James R. Neal has joined the company as Vice President, Business Development.

Biotech Stock Mailbag: Cardium Therapeutics (at TheStreet.com)

Fri, 13 Nov 2009 18:01:13 Etc/GMT

XOMA LTD /DE/ Financials (EDGAR Online Financials)

Fri, 13 Nov 2009 14:05:50 Etc/GMT

XOMA 052 Selected as a Top Ten Project to Watch (GlobeNewswire)

Thu, 12 Nov 2009 20:17:47 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced its anti-inflammatory antibody to interleukin-1 beta , XOMA 052, has been selected as a Top Ten Cardiovascular/metabolic Project to Watch for partnering opportunities.

XOMA Announces Presentation at Lazard Healthcare Conference on November 18 (GlobeNewswire)

Wed, 11 Nov 2009 19:30:14 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of antibody therapeutics, announced that Fred Kurland, Vice President and Chief Financial Officer of XOMA, is scheduled to present at the 6th annual Lazard Healthcare Conference on Wednesday, November 18, at 1:45 pm.

XOMA LTD /DE/ Files SEC form 10-Q, Quarterly Report (EDGAR Online)

Mon, 9 Nov 2009 20:44:10 Etc/GMT

Doc Offers Top Hep C Drug Picks: BioBuzz (at TheStreet.com)

Mon, 9 Nov 2009 18:54:15 Etc/GMT

XOMA Ltd. Q3 2009 Earnings Call Transcript (at Seeking Alpha)

Mon, 9 Nov 2009 18:19:08 Etc/GMT

Xoma Waffles on Timing of Drug Partnership: BioBuzz (at TheStreet.com)

Mon, 9 Nov 2009 15:23:17 Etc/GMT

XOMA Reports 2009 Third Quarter Financial Results (GlobeNewswire)

Mon, 9 Nov 2009 13:00:00 Etc/GMT

BERKELEY, Calif. -- XOMA Ltd. , a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the third quarter and nine months ended September 30, 2009 and provided a general business update.

Q3 2009 XOMA Ltd. Earnings Release - Before Market Open (CCBN)

Mon, 9 Nov 2009 12:07:20 Etc/GMT

Biosimilars, Biologics, Biotech And Specialty Pharmaceuticals: Piper Jaffray Picks The Stocks And Sectors With Highest Potential Returns For Investors (Wall Street Transcript)

Fri, 6 Nov 2009 15:15:00 Etc/GMT

67 WALL STREET, New York - November 6, 2009 - The Wall Street Transcript has just published its Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This 76 page feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.